The PEPI Trial is an important method of establishing, in as unambiguous a manner possible, the metabolic and clinical effects of estrogen/progestin combinations in post-menopausal women. This prospective randomized clinical trial will be the largest of its kind when the results are finally available. It may form the framework for a future and even larger study, regarding the effects of estrogen/progestin on disease outcome e.g., cardiovascular. Taken with this view the PEPI Trial assumes great importance. We have designed a clinical trial that compares two forms of estrogen preparations: Conjugated equine estrogen (CEE) and transdermal estradiol (TDE); and compares two forms of progestins: Medroxyprogesterone acetate (MPA) and micronized progesterone (P). First, post-menopausal women with intact uterus will be randomized to 6 groups: CEE + MPA; CEE + P; TDE + MPA; TDE + P; placebo patch + placebo pill; placebo pill + placebo pill. We can then compare the effect of different progestins in women on the same estrogen, and compare the effect of different estrogens in women on the same progestin. We can also compare each group against the placebo group. Second, past-menopausal women without uterus will be randomized of 3 groups; CEE, TDE, placebo (1/2 patch). From this group we can compare the effects of estrogen only to those with added progestin e.g., CEE + MPA vs VEE, and etc., estrogen only against placebo, and between the different estrogen preparations. This allows multiple comparisons of metabolic and clinical outcome variables. The investigators are excited and committed to the PEPI Trial because of its health importance. Our experience is considerable in the following areas: (1) Clinical trial protocol development, recruitment, maintenance and data quality; (2) establishment of population based normative data for bone density measurements; (3) presence of a fully functioning Lipid Research Clinic Care Lipid Laboratory and principal investigator interested in management of lipid disorders; (4) research in the psychological and sexual responses to illnesses; and (5) the presence of a first- rate epidemiological program.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL040195-03
Application #
3553219
Study Section
(SRC)
Project Start
1987-09-30
Project End
1992-07-31
Budget Start
1989-08-01
Budget End
1990-07-31
Support Year
3
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
Schools of Medicine
DUNS #
041294109
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Smith, E M; Johnson, S R; Ritchie, J M et al. (2004) Persistent HPV infection in postmenopausal age women. Int J Gynaecol Obstet 87:131-7
Greendale, Gail A; Espeland, Mark; Slone, Stacey et al. (2002) Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Intern Med 162:665-72
Lindenfeld, Etta A; Langer, Robert D (2002) Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial. Obstet Gynecol 100:853-63
Greendale, G A; Wells, B; Marcus, R et al. (2000) How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions Trial. Arch Intern Med 160:3065-71
Barrett-Connor, E; Espeland, M A; Greendale, G A et al. (2000) Postmenopausal hormone use following a 3-year randomized clinical trial. J Womens Health Gend Based Med 9:633-43
Cushman, M; Legault, C; Barrett-Connor, E et al. (1999) Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100:717-22
Legault, C; Stefanick, M L; Miller, V T et al. (1999) Effect of hormone replacement therapy on the validity of the Friedewald equation in postmenopausal women: the postmenopausal estrogen/progestins interventions (PEPI) trial. J Clin Epidemiol 52:1187-95
Barnabei, V M; Phillips, T M; Hsia, J (1999) Plasma homocysteine in women taking hormone replacement therapy: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Womens Health Gend Based Med 8:1167-72
Greendale, G A; Reboussin, B A; Sie, A et al. (1999) Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 130:262-9
Greendale, G A; Reboussin, B A; Hogan, P et al. (1998) Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 92:982-8

Showing the most recent 10 out of 23 publications